Safety and pharmacokinetics of the Fc-modified HIV-1 human monoclonal antibody VRC01LS: A Phase 1 open-label clinical trial in healthy adults.
Author | :
|
---|---|
Abstract | :
VRC01 is a human broadly neutralizing monoclonal antibody (bnMAb) against the CD4-binding site of the HIV-1 envelope glycoprotein (Env) that is currently being evaluated in a Phase IIb adult HIV-1 prevention efficacy trial. VRC01LS is a modified version of VRC01, designed for extended serum half-life by increased binding affinity to the neonatal Fc receptor. |
Year of Publication | :
2018
|
Journal | :
PLoS medicine
|
Volume | :
15
|
Issue | :
1
|
Number of Pages | :
e1002493
|
ISSN Number | :
1549-1277
|
URL | :
http://dx.plos.org/10.1371/journal.pmed.1002493
|
DOI | :
10.1371/journal.pmed.1002493
|
Short Title | :
PLoS Med
|
Download citation |